Trial Profile
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Jun 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary) ; Lomustine
- Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions; First in man
- Sponsors Eli Lilly and Company
- 10 Jun 2023 Planned End Date changed from 31 Dec 2023 to 30 Sep 2024.
- 13 Feb 2023 Planned End Date changed from 6 Dec 2023 to 31 Dec 2023.
- 18 Oct 2022 Planned End Date changed from 6 Dec 2022 to 6 Dec 2023.